Modified Double-Stranded RNAi Agent for Stable PCSK9 Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypercholesterolemia, such as statin drugs and PCSK9 monoclonal antibodies, suffer from adverse reactions, high cost, and frequent administration requirements, necessitating a more effective and stable inhibitor for PCSK9 gene expression.
Innovation Solution
A double-stranded RNAi agent comprising specific sense and antisense strands, with nucleotide lengths ranging from 14 to 30, and modifications like 2′-O-methyl and 2′-fluoro, conjugated with ligands for targeted PCSK9 gene silencing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PCSK9 monoclonal antibody is used for treatment, then PCSK9 inhibition efficacy is achieved, but treatment cost increases and administration frequency increases
Solution Approach 1:
The patent extracts the essential function of PCSK9 inhibition from complex monoclonal antibody therapy and implements it through a simplified siRNA mechanism that directly targets PCSK9 mRNA for degradation, eliminating the need for large protein molecules and complex immune system interactions
Solution Approach 2:
The siRNA agent is designed as a smaller, more stable molecule that can be administered less frequently (every 6 months vs. every 2-4 weeks), effectively replacing expensive, short-acting antibody therapies with a more economical, long-lasting solution
2Reliability
If siRNA is used to silence PCSK9 gene, then PCSK9 expression is inhibited, but drug stability and delivery efficiency need improvement
Solution Approach 1:
The patent applies extensive chemical modifications to the siRNA strands including 2'-O-methyl, 2'-fluoro, and phosphorothioate modifications at specific positions, which fundamentally change the physical and chemical parameters of the molecule to enhance stability against nucleases and improve cellular uptake while maintaining RNAi activity
Solution Approach 2:
The siRNA agent is constructed as a composite structure with modified nucleotide backbones and sugar moieties, combining different chemical components (ribose derivatives, phosphate analogs, base modifications) to create a molecule with enhanced stability and delivery properties while retaining biological function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agent effectively inhibits PCSK9 expression, providing long-term treatment with improved efficacy, specificity, and stability, reducing LDL-C levels and treating PCSK9-mediated diseases.
Implementation Method 1
RNA interference (RNAi) widely exists in natural species. After Andrew Fire and Craig Mello et al. first discovered the RNAi phenomenon in Caenorhabditis elegans (C. elegans) in 1998, and Tuschl and Phil Sharp et al. confirmed its existence in mammals in 2001
Data Source
AI summary
An RNAi agent inhibiting PCSK9 gene expression and an application thereof. The present invention relates to a modified double-stranded RNAi agent and an application thereof, and in particular to a double-stranded RNAi agent inhibiting PCSK9 gene expression and a pharmaceutical composition thereof, and an application of the double-stranded RNAi agent or the pharmaceutical composition thereof in the treatment of diseases mediated by PCSK9 expression.